Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

About this update from Kyverna Therapeutics, Inc.

[{"type":"image","alt":"Kyverna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kyverna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/6f9f28e393a47bcb20d3d0e1f187b2f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NgRte8yTQVY2_NCia6rH2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6f9f28e393a47bcb20d3d0e1f187b2f0","width":300,"height":120}},"lazy":false},{"type":"text","content":"– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –","length":92,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS).","length":447,"tagName":"p"},{"type":"text","content":"Conference Call Details","length":23,"tagName":"p"},{"type":"text","content":"Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join the call. The call can also be accessed via live webcast. The webcast and supporting presentation materials will be available on the "Events & Presentations" section of Kyverna's Investor Relations webpage at ir.kyvernatx.com. An archived replay will also be available on the website.","length":525,"tagName":"p"},{"type":"text","content":"Dial-In Registration Link:Conference Call Registration","length":55,"tagName":"p"},{"type":"text","content":"Webcast Link:Kyverna Topline Results for SPS Conference Call","length":61,"tagName":"p"},{"type":"text","content":"About KYV-101","length":13,"tagName":"p"},{"type":"text","content":"KYV-101 is a fully human, autologous, CD19 CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With a single administration, ...

More updates from Kyverna Therapeutics, Inc.